328 related articles for article (PubMed ID: 30130706)
1. Investigation of the effect of hepatic metabolism on off-target cardiotoxicity in a multi-organ human-on-a-chip system.
Oleaga C; Riu A; Rothemund S; Lavado A; McAleer CW; Long CJ; Persaud K; Narasimhan NS; Tran M; Roles J; Carmona-Moran CA; Sasserath T; Elbrecht DH; Kumanchik L; Bridges LR; Martin C; Schnepper MT; Ekman G; Jackson M; Wang YI; Note R; Langer J; Teissier S; Hickman JJ
Biomaterials; 2018 Nov; 182():176-190. PubMed ID: 30130706
[TBL] [Abstract][Full Text] [Related]
2. Analysis of reproducibility and robustness of a human microfluidic four-cell liver acinus microphysiology system (LAMPS).
Sakolish C; Reese CE; Luo YS; Valdiviezo A; Schurdak ME; Gough A; Taylor DL; Chiu WA; Vernetti LA; Rusyn I
Toxicology; 2021 Jan; 448():152651. PubMed ID: 33307106
[TBL] [Abstract][Full Text] [Related]
3. Human Induced Pluripotent Stem-Cardiac-Endothelial-Tumor-on-a-Chip to Assess Anticancer Efficacy and Cardiotoxicity.
Weng KC; Kurokawa YK; Hajek BS; Paladin JA; Shirure VS; George SC
Tissue Eng Part C Methods; 2020 Jan; 26(1):44-55. PubMed ID: 31797733
[TBL] [Abstract][Full Text] [Related]
4. Quantifying drug-induced structural toxicity in hepatocytes and cardiomyocytes derived from hiPSCs using a deep learning method.
Maddah M; Mandegar MA; Dame K; Grafton F; Loewke K; Ribeiro AJS
J Pharmacol Toxicol Methods; 2020 Sep; 105():106895. PubMed ID: 32629158
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity of cyclophosphamide's metabolites: an in vitro metabolomics approach in AC16 human cardiomyocytes.
Dionísio F; Araújo AM; Duarte-Araújo M; Bastos ML; Guedes de Pinho P; Carvalho F; Costa VM
Arch Toxicol; 2022 Feb; 96(2):653-671. PubMed ID: 35088106
[TBL] [Abstract][Full Text] [Related]
6. Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs.
Oleaga C; Bernabini C; Smith AS; Srinivasan B; Jackson M; McLamb W; Platt V; Bridges R; Cai Y; Santhanam N; Berry B; Najjar S; Akanda N; Guo X; Martin C; Ekman G; Esch MB; Langer J; Ouedraogo G; Cotovio J; Breton L; Shuler ML; Hickman JJ
Sci Rep; 2016 Feb; 6():20030. PubMed ID: 26837601
[TBL] [Abstract][Full Text] [Related]
7. Human iPSC-based cardiac microphysiological system for drug screening applications.
Mathur A; Loskill P; Shao K; Huebsch N; Hong S; Marcus SG; Marks N; Mandegar M; Conklin BR; Lee LP; Healy KE
Sci Rep; 2015 Mar; 5():8883. PubMed ID: 25748532
[TBL] [Abstract][Full Text] [Related]
8. Concise Review: Precision Matchmaking: Induced Pluripotent Stem Cells Meet Cardio-Oncology.
Nair P; Prado M; Perea-Gil I; Karakikes I
Stem Cells Transl Med; 2019 Aug; 8(8):758-767. PubMed ID: 31020786
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Cardiotoxicity With Stem Cell-based Strategies.
Stella Stoter AM; Hirt MN; Stenzig J; Weinberger F
Clin Ther; 2020 Oct; 42(10):1892-1910. PubMed ID: 32938533
[TBL] [Abstract][Full Text] [Related]
10. Assessment of beating parameters in human induced pluripotent stem cells enables quantitative in vitro screening for cardiotoxicity.
Sirenko O; Cromwell EF; Crittenden C; Wignall JA; Wright FA; Rusyn I
Toxicol Appl Pharmacol; 2013 Dec; 273(3):500-7. PubMed ID: 24095675
[TBL] [Abstract][Full Text] [Related]
11. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
[TBL] [Abstract][Full Text] [Related]
12. Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.
Doherty KR; Talbert DR; Trusk PB; Moran DM; Shell SA; Bacus S
Toxicol Appl Pharmacol; 2015 May; 285(1):51-60. PubMed ID: 25841593
[TBL] [Abstract][Full Text] [Related]
13. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings.
Zwartsen A; de Korte T; Nacken P; de Lange DW; Westerink RHS; Hondebrink L
J Mol Cell Cardiol; 2019 Nov; 136():102-112. PubMed ID: 31526813
[TBL] [Abstract][Full Text] [Related]
15. High-Content Assay Multiplexing for Toxicity Screening in Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Hepatocytes.
Grimm FA; Iwata Y; Sirenko O; Bittner M; Rusyn I
Assay Drug Dev Technol; 2015 Nov; 13(9):529-46. PubMed ID: 26539751
[TBL] [Abstract][Full Text] [Related]
16. Toxicity testing and drug screening using iPSC-derived hepatocytes, cardiomyocytes, and neural cells.
Csöbönyeiová M; Polák Š; Danišovič L
Can J Physiol Pharmacol; 2016 Jul; 94(7):687-94. PubMed ID: 27128322
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of dual-cardiotoxicity evaluation method based on analysis of field potential and contractile force of human iPSC-derived cardiomyocytes / multielectrode assay platform.
Lee SG; Kim J; Oh MS; Ryu B; Kang KR; Baek J; Lee JM; Choi SO; Kim CY; Chung HM
Biochem Biophys Res Commun; 2021 May; 555():67-73. PubMed ID: 33813278
[TBL] [Abstract][Full Text] [Related]
18. Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes as an in vitro model in toxicology: strengths and weaknesses for hazard identification and risk characterization.
Burnett SD; Blanchette AD; Chiu WA; Rusyn I
Expert Opin Drug Metab Toxicol; 2021 Aug; 17(8):887-902. PubMed ID: 33612039
[TBL] [Abstract][Full Text] [Related]
19. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
Yang X; Papoian T
J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
[TBL] [Abstract][Full Text] [Related]
20. Deep learning detects cardiotoxicity in a high-content screen with induced pluripotent stem cell-derived cardiomyocytes.
Grafton F; Ho J; Ranjbarvaziri S; Farshidfar F; Budan A; Steltzer S; Maddah M; Loewke KE; Green K; Patel S; Hoey T; Mandegar MA
Elife; 2021 Aug; 10():. PubMed ID: 34338636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
